Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
Read More

Reported Late Wednesday, Oramed Pharmaceuticals Announces Top-line Results From Phase 3 Trial Of ORMD-0801 For The Treatment Of Type 2 Diabetes; The ORA-D-013-1 Trial Did Not Meet Its Primary Endpoint

Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, announced today top-line results from its Phase 3 randomized, double-blind, placebo-controlled, multicenter clinical trial (ORA-D-013-1) comparing the efficacy of ORMD-0801 to placebo in patients with Type 2 Diabetes (T2D) at 26 weeks.